What is CT041, and how is it different from a drug infusion?
CT041, satri-cel and satricabtagene autoleucel refer to the same CLDN18.2-targeted autologous CAR-T product. Your own T cells are collected, engineered and expanded outside the body, then infused to recognize cancer cells carrying the target.
The cells are manufactured for each patient. The decision therefore depends on both the cancer profile and whether your health, disease course and available time allow the full treatment process. Start with eligibility and the treatment steps below.
Where is CT041 available, and do I need a trial?
There is an approved treatment pathway in China; access is not limited to clinical trials. The manufacturer announced approval on June 22, 2026 for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after failure of at least two prior treatment lines—the first CAR-T product approved for a solid tumor.
The manufacturer has reported commercial rollout, and Shanghai Jiahui International Cancer Center has announced that it will be among the initial institutions offering the therapy. For an international patient, the next step is to confirm the treating team, product arrangements and manufacturing schedule before booking travel for infusion.
What can Chirona arrange?
We arrange gastric-cancer and cell-therapy specialist review through partner hospitals in China, and coordinate record review, further tests and care. Once the team confirms suitability, we coordinate collection, manufacturing and infusion plans, hospital monitoring and a written estimate. The treating hospital and available dates are confirmed before travel.
What about other countries or earlier-stage disease?
Chinese approval does not establish routine access or insurance coverage in the US, Australia, New Zealand or Turkey. Earlier-stage disease, fewer than two failed treatment lines, HER2-positive cancer and pancreatic cancer do not automatically fit this approved pathway. Research access requires a separate check of a specific trial’s current recruitment and eligibility.
What benefit has been shown after previous stomach cancer treatments?
The randomized phase II CT041-ST-01 study enrolled patients with CLDN18.2-positive advanced gastric or gastroesophageal junction cancer after at least two failed treatment lines. CT041 improved median progression-free survival compared with physician-selected medicines, supporting a later-line option for eligible patients.
| Trial feature | Reported result | What it helps explain |
|---|---|---|
| Randomized groups | 104 satri-cel; 52 physician’s choice | The primary analysis included randomized patients, not only those infused. |
| Received study treatment | 88 in the satri-cel group; 48 controls | Reaching treatment matters; discuss contingencies before collection. |
| Median progression-free survival | 3.25 versus 1.77 months | PFS concerns progression or death; it is not an individual life-expectancy estimate. |
3.25 months is not an estimate of your life expectancy
This is the study’s median time to progression or death, not overall survival or the duration every patient will benefit. Some benefit longer and some do not respond. Symptoms, disease pace and the feasibility of completing cell therapy also matter.
Zolbetuximab occupies a different treatment setting
US-approved zolbetuximab with chemotherapy is a first-line option for the corresponding CLDN18.2-positive, HER2-negative gastric or GEJ population. CT041’s Chinese indication is later-line CAR T. Mechanisms, testing and delivery differ; no direct head-to-head result supports a simple ranking.
Which stomach cancer patients may be eligible?
Start with the approved disease profile below, then assess fitness with the treating team. CLDN18.2 positivity is one requirement, not a stand-alone treatment qualification.
| Check | What matters | What to send |
|---|---|---|
| Diagnosis and stage | Advanced gastric or gastroesophageal junction adenocarcinoma; other stomach tumors are different diagnoses. | Full pathology, recent imaging and staging records. |
| CLDN18.2 | Positive, with an assay result acceptable under the current product requirements—not just a positive/negative summary. | IHC report, staining intensity, positive-cell percentage, assay and specimen date. |
| HER2 | Negative. Incomplete or uncertain results need pathology review. | HER2 IHC and any ISH/FISH results. |
| Previous treatment | At least two failed treatment lines; two infusion cycles do not count as two lines. | Regimens, dates, response and reason each line ended. |
What if my report only says “CLDN18.2 positive”?
Send the full report before arranging another biopsy yourself. We coordinate review of the assay, staining intensity, positive tumor-cell percentage and specimen date. The team then decides whether existing slides, a tissue block or further testing are needed. Trial cutoffs are not automatically a universal commercial-use rule.
Can I be assessed after targeted therapy or immunotherapy?
A specialist can review the complete treatment history. Include chemotherapy, immunotherapy and HER2- or CLDN18.2-directed drugs, especially prior zolbetuximab and any progression on it. Lines and reasons for stopping need individual review; previous treatment against the same target does not by itself establish benefit or rule CT041 out.
What if I have peritoneal spread, ascites or difficulty eating?
Patients with peritoneal metastases were included in the randomized study, so this finding alone need not end the assessment. The team also reviews ascites, nutrition, activity, bleeding or obstruction, infection, blood counts and organ function, and whether disease can be managed until infusion. Include recent weight changes, food intake, ascites treatment and current supportive care.
What happens from assessment to CAR-T infusion?
You can start with a record review before traveling. These are the main steps in autologous CAR-T care; the treating center sets the CT041 medicines, collection and infusion schedule according to product requirements and your condition.
| Step | What happens | Confirm ahead |
|---|---|---|
| 1. Specialist screening | Review pathology, markers, previous treatment and fitness. | Missing records, further tests and center acceptance. |
| 2. T-cell collection | Collect your own T cells from blood by apheresis. | Collection date, venous access and current medicines. |
| 3. Manufacturing and interim care | Engineer and expand cells, then perform quality checks; bridging treatment may control disease meanwhile. | Expected completion and where interim treatment and checks occur. |
| 4. Preparation and infusion | Reassess health and disease, give lymphodepleting preparation, then infuse the cells. | Product release, fitness to proceed and hospital arrangements. |
| 5. Monitoring and return home | Monitor inflammatory reactions, blood counts and gut symptoms; plan response checks and ongoing follow-up. | Discharge and travel clearance, caregiver, checks and urgent contacts. |
How long must I stay, and am I hospitalized while waiting?
Manufacturing, hospital monitoring and nearby follow-up are separate phases; they do not necessarily mean one continuous admission. We coordinate a phase-by-phase schedule and confirm where interim care can take place. Return travel depends on recovery, test results and the treating clinician’s clearance, not the infusion date alone.
What if my condition changes before the cells are ready?
Agree on bridging and a backup plan before collection. Infection, significant progression or delayed product release may change infusion timing, treatment choices and costs already incurred. Collection does not guarantee infusion; advance planning helps maintain continuity of care.
What continues after infusion?
Observation and follow-up continue after infusion. One infusion does not mean treatment is finished or recurrence is prevented. Further anticancer therapy or another infusion requires reassessment of response, tolerability and product requirements.
Which risks need close monitoring and prompt treatment?
CT041 requires a team experienced in cell therapy and equipped for urgent treatment. Monitoring focuses on low blood counts, infection and cytokine release syndrome (CRS), with particular attention to eating, bleeding and gastrointestinal symptoms in stomach cancer.
Inflammation, infection and blood counts
Fever, breathing difficulty or marked dizziness need prompt assessment. Infection and inflammatory toxicity can overlap. Low blood counts may affect infection and bleeding risk; follow the team’s monitoring instructions.
Do not dismiss new gastrointestinal symptoms
The cancer and treatment can both cause gastrointestinal problems. Contact the team immediately for new or worsening abdominal pain, vomiting blood, black stools, persistent vomiting or inability to eat. Severe bleeding, breathing difficulty or altered awareness requires emergency care.
Plan the handover before returning home
Carry the product name, infusion date, treatment summary and emergency contacts. Confirm who will monitor recovery locally and how persistent low counts, infection or new symptoms will be discussed with the treating center.
What could one CT041 treatment course cost?
US$149,000–254,000
What’s included
This estimate covers total medical treatment costs for one CAR-T treatment pathway, including the CAR-T cell product, specialist consultations and assessment, pretreatment tests, cell collection, conditioning treatment, cell infusion and nursing, necessary hospitalization and monitoring, routine supportive care, and early follow-up tests. Travel and accommodation are not included.
Your individual treatment costs
Further testing, bridging treatment, hospital stay, complications and follow-up can take the total outside this estimate. We help obtain an itemized medical estimate covering the product, collection, preparation, infusion and monitoring, and clarify charges for serious complications, ICU care, another infusion or additional anticancer treatment. Coordination, travel and accommodation costs are confirmed separately.
Before collection and payment, clarify how costs are handled if manufacturing is delayed, the product cannot be released or you become unable to receive infusion. Written hospital and service terms should distinguish completed services from those not delivered.
How does Chirona coordinate assessment, treatment and follow-up?
Start by sharing the records you already have. We organize them for the treating team, arrange gastric-cancer and cell-therapy specialist review, and turn the findings into a plan for tests, appointments, timing and costs.
1. Send the records that determine eligibility
- Full pathology, CLDN18.2 and HER2 reports; tell us whether slides or tissue blocks are available for review.
- Each treatment line, dates, response and reason for stopping, plus recent imaging reports and scan files.
- Recent blood tests, current medicines and changes in weight, eating, ascites, bleeding, infection or daily activity.
2. Get a clear plan before travel
We coordinate answers from the partner hospital on suitability, missing tests, consultation and collection dates, care during manufacturing and itemized costs. We then arrange appointments, language support and travel coordination. If CT041 is not suitable now, the specialist can also compare preparatory care or alternatives.
3. Connect follow-up after discharge
We help organize treatment and infusion records, the follow-up plan and urgent contacts for handover to your home clinicians. Before discharge, confirm blood-test and imaging schedules, symptoms needing urgent care and whether you are cleared to travel.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.
- CARsgen: satri-cel Chinese approval announcement
- The Lancet: CT041-ST-01 randomized Phase II trial
- FDA: zolbetuximab with chemotherapy for CLDN18.2-positive gastric/GEJ cancer
- NCI · T-cell transfer therapy
- Memorial Sloan Kettering · CAR T-cell patient and caregiver guide
- Nature Medicine · CT041 phase 1 final results
- CARsgen: 2026 interim results and satri-cel commercial rollout
- Jiahui International Cancer Center: CT041 approval and planned clinical access